Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report published on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Performance

Shares of NASDAQ:TENX opened at $3.87 on Friday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $61.20. The business has a fifty day moving average price of $3.51 and a 200-day moving average price of $3.69.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, beating the consensus estimate of ($1.99) by $0.16. As a group, equities analysts anticipate that Tenax Therapeutics will post -6.87 EPS for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.